There’s a lot of talk about “antibiotic resistance” in the US and the UK, and it’s not all bad news.
But when you dig a little deeper, there’s an even more pressing issue at play here.
One of the most troubling aspects of antibiotic shortages is that they’re often not caused by “antimicrobial resistance” and are actually caused by shortages of antibiotics that people are already taking.
And that means that those of us who need antibiotics are already under pressure.
And that’s something that government needs to be concerned about.
In a report to the government published this week, a coalition of advocacy groups and researchers say that the US government is in dire need of a solution to this situation.
The group recommends that the government provide financial incentives for antibiotic manufacturers to move towards generic production to help address the shortage.
The US has a severe shortage of generic antibiotics for the treatment of pneumonia, strep throat, and a host of other conditions.
It’s the second-largest supply of antibiotics in the world, after China, and with the price of antibiotics skyrocketing over the past few years, the situation is dire.
The group points to the increasing demand from hospitals and healthcare workers for new antibiotics.
And as a result, hospitals and medical workers are often the ones that have to go out and purchase these drugs, and those patients are often people who are already suffering from antibiotic-resistant infections.
In the report, the researchers from the American Academy of Infectious Diseases (AID) and the American Society for Microbiology (ASMB) argue that the current federal government has a huge opportunity to tackle the problem.
The AID and ASMB recommend that the Department of Health and Human Services (HHS) and other agencies create a “comprehensive strategy” to address the antibiotic shortage by investing in research and development (R&D) and manufacturing capacity to make new antibiotics more widely available.
The recommendations would see the US provide $4.4 billion to the Department, which would be split equally between R&D and manufacturing.
The money would be used to create a new industry that would provide cheaper generic antibiotics, as well as to help farmers to grow cheaper generic drugs.
The AID calls the strategy “a new approach to addressing antibiotic shortages.”
As a result of the new strategy, the government would be able to produce more generic drugs in a shorter time period.
And it would also allow the US to produce better antibiotics in an even shorter time frame.
The report says the new approach could also create a path for the US pharmaceutical industry to transition from the manufacturing phase to a R&d phase.
In addition, the plan would also include a $500 million research grant for a biotechnology company to develop a drug for the same condition as the one currently being used.
The plan also suggests that the new industry could be used for research to identify new drugs that might have greater efficacy and less side effects.
So, in summary, it sounds like the government could create incentives for pharmaceutical companies to get into the generic business and make generic drugs cheaper, easier to use, and better at treating serious infections.
It would also help to ensure that antibiotic-resistance-free people get the drugs they need.
But the AID’s and ASMB’s report does acknowledge that the problem is not limited to the US.
In Canada, for example, the shortage of generics has led to an increase in hospitalizations and antibiotic use, as many Canadians are turning to non-prescription antibiotics instead.
There’s also a shortage in the UK.
As a result there are more antibiotic prescriptions written in the country than there are people being treated with them.
And the number of prescriptions written has increased over the last decade.
So it’s certainly possible that in the future there will be an increase of antibiotic prescriptions and drug use.
But the current situation means that governments across the globe need to take note of the US problem and figure out how to solve it.
For more news on the topic of antibiotic resistance, read this.